Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for individuals afflicted with autoimmune diseases. Headquartered in Emeryville, California, the company's core mission is to liberate autoimmune patients through the curative potential of cell therapy, aiming to provide long-lasting, treatment-free remission by resetting the immune system.

Kyverna's primary therapeutic focus revolves around its lead candidate, mivocabtagene (miv-cel, KYV-101), an autologous CD19 CAR T-cell therapy. This therapy, along with other pipeline candidates like KYV-102 and KYV-201, targets B-cell-driven autoimmune diseases such as Stiff Person Syndrome (SPS), Myasthenia Gravis (MG), Multiple Sclerosis (MS), Lupus Nephritis, and Systemic Sclerosis. The company leverages advanced T-cell engineering and synthetic biology to suppress and eliminate autoreactive immune cells, offering a novel approach to treating these conditions.

Kyverna Therapeutics became publicly traded on the Nasdaq Global Select Market under the ticker symbol "KYTX" following its initial public offering on February 8, 2024, which raised $319 million. In September 2024, Warner Biddle was appointed CEO, and Christi Shaw became Executive Chairperson of the Board in January 2026. The company is actively progressing its clinical pipeline, with a Biologics License Application (BLA) submission for SPS anticipated in the first half of 2026 and a commercial launch expected by year-end 2026. Recent data presentations in April 2026 highlighted positive registrational trial results for miv-cel in SPS and promising longer-term Phase 2 data for generalized Myasthenia Gravis. Additionally, Kyverna secured up to $150 million in non-dilutive financing in November 2025, extending its cash runway into 2027 or 2028.